Search results
Results From The WOW.Com Content Network
MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007), was a decision by the Supreme Court of the United States involving patent law. [1] It arose from a lawsuit filed by MedImmune which challenged one of the Cabilly patents issued to Genentech.
One may still issue a patent challenge in a District Court, rather than request an inter partes review. [6] As of mid-2017, over a thousand patents have been cancelled as a result of the inter partes review process, and there were more inter partes review cases heard through mid-2017 compared to any individual circuit court. [6]
After a trial court awarded damages to Commil, Cisco appealed and argued that the trial court erroneously instructed the jury that the standard for inducement was negligence and precluded the submission of evidence of Cisco's good-faith belief that Commil's patent was invalid. The U.S. Court of Appeals for the Federal Circuit reversed and held ...
The U.S. Supreme Court on Tuesday declined to hear patent-licensing company VirnetX's bid to revive a $502.8 million jury verdict it won against Apple in a dispute over internet-security patents.
In addition to opposition proceedings, several other mechanisms enable third parties to influence the patent granting process or challenge patents: Third-party observations : Individuals or entities can submit observations on the patentability of an invention during the examination phase, providing relevant prior art or arguments without ...
Nautilus, Inc. v. Biosig Instruments, Inc., 134 S.Ct. 2120 (2014), was a 2014 decision by the United States Supreme Court pertaining to the interpretation (clarity, definiteness) of patent claims in U.S. patents. The opinion addressed the requirement contained in 35 U.S.C. § 112, ¶ 2 that a patent be "particularly pointing out and distinctly ...
The U.S. Supreme Court will only review cases on a discretionary basis and rarely decides patent cases. Unless overruled by a Supreme Court case, Federal Circuit decisions can dictate the results of both patent prosecution and litigation as they are universally binding on all United States district courts and the United States Patent and ...
A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought ...